Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
Key facts
- Who runs it
- Queen Mary University of London
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 130 people enrolled
- Started
- 11 Nov 2021
- Ended
- 31 Dec 2025
- Type of study
- Observational, 2 groups
- Record updated
- 2 March 2026
Who can take part
- Age
- 18 years to 120 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Adult (≥ 18 years)
- Patients with a probable (50-90% likelihood) or highly probable (>90% likelihood) diagnosis of cardiac sarcoidosis (CS) by a multidisciplinary team meeting in a CS-specialist centre as per the WASOG criteria
- Patients attending outpatient clinics in a CS-specialist centre
Who cannot take part
- Unable or unwilling to give informed consent
- Unable or unwilling to give and/or complete the study questionnaires • Inability to understand written and/or verbal English
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
What is the purpose of this research?
Read full original descriptionShow less
This study includes two parts based in two NHS specialist centres for cardiac sarcoidosis:
* Development of the CARD-SARC: Development of the new questionnaire to measure quality of life in cardiac sarcoidosis patients (the CARD-SARC questionnaire) * Validation of the CARD-SARC: Evaluation of how good the CARD-SARC questionnaire is at measuring quality of life changes in patients with cardiac sarcoidosis.
The 2 groups in the trial
- Development of the CARD-SARC (n=20)
* Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy. * Field-testing: 20 participants using a convenience/consecutive sampling strategy.
- Validation of the CARD-SARC (n=100)
The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 2 March 2026